iRGD peptide-engineered PROTAC nanoparticles achieved 67% PD-L1 degradation with deep tumor penetration, outperforming conventional immune checkpoint approaches.
67% degradationPROTAC nanoparticles achieved 67% PD-L1 protein degradation with iRGD-mediated tumor penetration
What the researchers found
Cyclic iRGD peptide-engineered PROTAC nanoparticles achieved 67% PD-L1 degradation with enhanced tumor penetration via integrin/neuropilin-1 pathways.
Why it matters
Degrading PD-L1 rather than blocking it could provide more durable anti-cancer immunity with lower drug doses and fewer side effects.
The numbers in context
67.05% PD-L1 degradation at 5 uM over 24 hours; iRGD peptide targets integrin and neuropilin-1; tested in MC38 colon cancer mouse model.
How the study worked
Rational PROTAC design, peptide-nanoparticle engineering, and preclinical tumor penetration and efficacy evaluation.
Who was studied
N/A (cancer cell lines and mouse tumor models)
What this study cannot tell us
Preclinical study — human tumor penetration, safety, and immune response need clinical validation.
How to read the evidence
Preclinical drug development study — innovative technology platform but requires clinical translation.
When this study was published
Published in 2025 in J Med Chem, reflecting cutting-edge cancer drug delivery technology.
The bigger picture
This converges peptide biology, protein degradation technology, and nanomedicine to create a next-generation cancer immunotherapy platform.
Questions still open
- How does PD-L1 degradation compare to PD-L1 blockade for immune activation?
- Can the iRGD platform deliver other therapeutic payloads?
Common questions
What is a PROTAC?
How does the iRGD peptide help?
Read the original research
Rational Design of PROTAC Degraders and Their Spatiotemporal Controlled Delivery for Enhanced Tumor Penetration and PD-L1 Protein Degradation.
Journal of medicinal chemistry, 68(21), 22665-22688
Citation
Qi, Qianqian; Zhang, Zhanyu; Ji, Xiang; Wang, Dun. (2025). Rational Design of PROTAC Degraders and Their Spatiotemporal Controlled Delivery for Enhanced Tumor Penetration and PD-L1 Protein Degradation.. Journal of medicinal chemistry, 68(21), 22665-22688. https://doi.org/10.1021/acs.jmedchem.5c01632